PL2578212T3 - Związek hamujący aktywację enzymu Erk 1/2 do zastosowania w leczeniu chorób neurodegeneracyjnych - Google Patents

Związek hamujący aktywację enzymu Erk 1/2 do zastosowania w leczeniu chorób neurodegeneracyjnych

Info

Publication number
PL2578212T3
PL2578212T3 PL10852058T PL10852058T PL2578212T3 PL 2578212 T3 PL2578212 T3 PL 2578212T3 PL 10852058 T PL10852058 T PL 10852058T PL 10852058 T PL10852058 T PL 10852058T PL 2578212 T3 PL2578212 T3 PL 2578212T3
Authority
PL
Poland
Prior art keywords
neurogenerative
erk1
illnesses
enzyme
treatment
Prior art date
Application number
PL10852058T
Other languages
English (en)
Inventor
Medrano Pilar Navarro
Puigjane Elisabet Gregori
Del Olmo Marisol Montolio
Redondo Ana Jiménez
López Jordi Mestres
Original Assignee
Farmalider Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmalider Sa filed Critical Farmalider Sa
Publication of PL2578212T3 publication Critical patent/PL2578212T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL10852058T 2010-05-24 2010-05-24 Związek hamujący aktywację enzymu Erk 1/2 do zastosowania w leczeniu chorób neurodegeneracyjnych PL2578212T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/ES2010/000228 WO2011147999A1 (es) 2010-05-24 2010-05-24 Compuesto inhibidor de la activación de la enzima erk1/2 para su uso en el tratamiento de enfermedades neurodegenerativas
EP10852058.6A EP2578212B1 (en) 2010-05-24 2010-05-24 Compound inhibiting activation of the enzyme erk1/2 for use in the treatment of neurogenerative illnesses

Publications (1)

Publication Number Publication Date
PL2578212T3 true PL2578212T3 (pl) 2017-01-31

Family

ID=45003358

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10852058T PL2578212T3 (pl) 2010-05-24 2010-05-24 Związek hamujący aktywację enzymu Erk 1/2 do zastosowania w leczeniu chorób neurodegeneracyjnych

Country Status (4)

Country Link
US (1) US9000047B2 (pl)
EP (1) EP2578212B1 (pl)
PL (1) PL2578212T3 (pl)
WO (1) WO2011147999A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016138130A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Use of pridopidine to improve cognitive function and for treating alzheimer's disease
CN115697386A (zh) * 2020-03-24 2023-02-03 泰伦基国际有限公司 一种治疗帕金森病的方法和药物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061774A (en) * 1974-03-02 1977-12-06 Lilly Industries, Limited Halogenated amino methyl adamantane derivatives
DE58905637D1 (de) 1989-04-14 1993-10-21 Merz & Co Gmbh & Co Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie.
GB9901691D0 (en) 1999-01-26 1999-03-17 Cerebrus Ltd Chemical compounds
GB0018272D0 (en) 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
CN100339070C (zh) * 2002-10-24 2007-09-26 莫茨药物股份两合公司 包含1－氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物
US20050113458A1 (en) 2003-10-22 2005-05-26 Forest Laboratories, Inc. Use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic a-beta peptides in amyloidopathies
CA2592320C (en) 2004-12-22 2015-11-24 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
EP1746092A1 (en) 2005-07-22 2007-01-24 Exonhit Therapeutics SA Compounds and methods for treatment of amyloid-B-peptide related disorders
WO2007017509A1 (de) 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Verbindungen zur behandlung der alzheimer erkrankung
CA2618481A1 (en) 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Compounds for treating alzheimer's disease
EP1915339A1 (de) 2005-08-11 2008-04-30 Boehringer Ingelheim International GmbH Inhibitoren der beta-sekretase zur behandlung der alzheimer- erkrankung
JP2009504613A (ja) 2005-08-11 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病の治療用化合物
ES2341517B1 (es) * 2008-03-28 2011-01-25 Farmalider, S.A Utilizacion de un compuesto inhibidor de la activacion de la enzima erk 1/2 en el tratamiento de enfermedades neurodegenerativas.

Also Published As

Publication number Publication date
EP2578212B1 (en) 2016-07-06
EP2578212A4 (en) 2013-11-06
EP2578212A1 (en) 2013-04-10
US20130065966A1 (en) 2013-03-14
WO2011147999A1 (es) 2011-12-01
US9000047B2 (en) 2015-04-07

Similar Documents

Publication Publication Date Title
HRP20181185T1 (hr) Inhibitori ibat za liječenje bolesti jetre
PL2205273T3 (pl) Zastosowanie zmodyfikowanych komórek w leczeniu stwardnienia rozsianego
HK1208237A1 (en) Methods for the treatment of gout
HK1187606A1 (zh) 取代的 -稠合含氮雜環化合物及其用途
EP2361089A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED FUNCTION OF -SYNUCLEINE
PL2646425T3 (pl) Kwasy indanyloksydihydrobenzofuranylooctowe użyteczne do leczenia zespołu metabolicznego
PT3042910T (pt) 2'-espiro-nucleósidos para utilização na terapia da hepatite c
EP2456757A4 (en) HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME
AP2013006984A0 (en) BicycloÄ3.2.1Üoctyl amide derivatives and uses of same
EP2488025A4 (en) SEPIAPTERIC INTREDUCTASE INHIBITION FOR PAIN TREATMENT
EP2686688A4 (en) SYSTEMS AND COMPOSITIONS FOR DIAGNOSIS OF BARRETT OSOPHAGES AND METHOD OF USE THEREOF
PT2521703T (pt) Compostos fosfatados e a sua utilização como fertilizantes
IL223865A0 (en) Calcium salts of dihydrooroorotate dehydrogenase inhibitors, compositions comprising the same and uses thereof
HK1151304A1 (en) Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
PL2276498T3 (pl) Zastosowanie bakterii probiotycznych do leczenia hiperhomocysteinemii
HK1180182A1 (en) Platelet-derived growth factor compositions and methods for the treatment of tendinopathies
EP2488507A4 (en) NOVEL MEK INHIBITORS USEFUL IN THE TREATMENT OF DISEASES
PL2578212T3 (pl) Związek hamujący aktywację enzymu Erk 1/2 do zastosowania w leczeniu chorób neurodegeneracyjnych
PL2460509T3 (pl) Kompozycja do leczenia brodawek
HK1139050A1 (en) Medicament for the treatment of pneumonia
GB201016486D0 (en) Compounds for the use in treatment of plants
EP2309859A4 (en) ENZYME INHIBITORS AND USE THEREOF
EP2544534A4 (en) COMPOSITIONS, METHODS AND DEVICES USED IN THE TREATMENT OF DYSMENORRHEA
PL2229943T3 (pl) Związek do zastosowania w leczeniu neuropatii obwodowych
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia